Erlotinib: A successful clinical case and some notes about hepatic toxicity.
A case of a woman with lung adenocarcinoma in which fifteen-month disease control was achieved with second-line erlotinib treatment is presented. Five months after treatment beginning, isolated grade 3 hyperbilirubinemia occurred and daily dose was reduced to 100mg. Comments on erlotinib hepatic toxicity and the pharmacologic interactions on erlotinib metabolism are given. Rev Port Pneumol 2008; XIV (Supl 3): S29-S34.